Study at a glance
How was vitamin D studied in recovery from burns and broken bones?
This review brings together human trials and animal experiments on vitamin D and recovery after burns, broken bones and skin injury. The studies used different forms of vitamin D, doses and treatment times. Changes in blood tests or cell activity do not necessarily mean that tissue heals better.
Did vitamin D help burns or broken bones heal in people?
In a trial of 54 adults with serious burns, vitamin D3 improved wound scores. It did not show the same benefit for pain or infection measures, and the higher dose was not clearly better. Fracture results were mixed. A trial of 102 adults found no benefit in its planned healing comparisons. A small wrist-fracture study found worse results for some estimates of bone strength with larger doses given at intervals. Another small study reported faster healing with weekly treatment, but compared two different total doses and had no group without vitamin D.
Did less inflammation always mean better healing in mice?
Some vitamin D compounds improved selected measures of bone repair or skin injury in mice. However, giving calcitriol, the active vitamin D hormone, early at a fracture site reduced some inflammation signals while making healing worse. Starting later did not clearly speed or slow overall healing. Less inflammation therefore did not always mean better repair. These experiments cannot be treated as tests of ordinary vitamin D3 taken by mouth in people.
Do these studies show that vitamin D consistently speeds healing?
The human studies were small and had different patients, injuries and methods. Some positive findings came from less reliable comparisons or analyses chosen after the results were examined. Improved wound scores, scan results and cell markers describe different aspects of recovery. The evidence does not establish a consistent fracture-healing benefit, an ideal dose or a general promise of faster recovery.
Read the full article below ↓Research on vitamin D and tissue repair contains promising findings, null results and results that depend on the treatment’s timing or form. A small burn trial reported better wound scores, while human fracture studies produced mixed outcomes. Animal experiments help explain possible mechanisms, but they also show that reducing early inflammation can impair structural recovery. This review first examines repair outcomes, then considers how inflammatory resolution relates to the restoration of tissue. Vitamin D, Injury Recovery and Inflammation Resolution: Study Summary.
Repair following injury or stress
Repair is a sequence of overlapping events rather than one laboratory measurement. A wound can become smaller without every aspect of tissue quality improving. A fracture can show radiographic changes without a matching change in pain or function. A cellular marker may change before any structural recovery is demonstrated. These distinctions are central to interpreting Vitamin D and Tissue Repair.
The studies also used different interventions. Oral vitamin D3 in hospital patients is not interchangeable with locally injected calcitriol in mice or with an experimental metabolite given after osteotomy. A comparison of two supplementation regimens does not test vitamin D against no vitamin D. Keeping these design features visible prevents a plausible mechanism from being mistaken for a general treatment effect.
A small randomised burn trial
Ghadimi and colleagues studied fifty-four adults hospitalised with burns affecting 20% to 50% of total body surface area. Participants were assigned to placebo, 1,000 IU vitamin D3 daily or 3,000 IU daily, with eighteen people in each group. Treatment ran from admission to discharge, and most participants were vitamin-D deficient. The study was described as randomised and double-blind.
At the second week, the Bates-Jensen Wound Assessment Tool (BWAT), a structured assessment of wound characteristics in which lower scores indicate better healing, showed mean scores of 33.80 in controls, 28.22 with 1,000 IU and 25.44 with 3,000 IU. The corresponding standard deviations were 6.25, 7.72 and 5.88. Table 5 reports control comparisons of p = 0.049 and p = 0.003, respectively, with adjustment for admission weight. The low-dose versus high-dose comparison was not significant (p = 0.45). This supports a positive signal in the small clinical setting, but not superiority of the higher dose.
Selected scar outcomes differed at three months. Other outcomes, including infection-related measures, blood culture, additional antibiotics and pain, did not show the same benefit. A report of improved wound scores should not be expanded into a claim that the intervention prevented infection or improved every aspect of recovery. Wound scores, scar assessments and patient symptoms answer different questions.
Several limitations reduce confidence in the size and reliability of the effect. The study had small groups, baseline imbalances and multiple outcomes. Recruitment began before the recorded registration date, limiting assurance that all reported analyses were specified in advance. Some data fields were inconsistent; insulin and temperature results are not used here because their reporting could not support a dependable interpretation.
The study provides direct human evidence relevant to Vitamin D and Skin, but its setting was specialised hospital care. It does not establish benefit for every wound type, an optimal dose or a reason to replace standard burn treatment. The appropriate conclusion is a clinical signal that needs replication with clearly specified outcomes and stronger reporting.
Fracture recovery in a screening trial
The Vita-Shock phase II trial studied 102 adults aged eighteen to fifty with tibial or femoral fractures treated with intramedullary nails. Its four arms were 150,000 IU at injury and again at six weeks, 4,000 IU daily, 600 IU daily, or placebo; daily treatment lasted three months. These research regimens are not recommendations. Clinical recovery was assessed with the Function IndeX for Trauma (FIX-IT), which evaluates pain and weight-bearing function, while the Radiographic Union Score for Tibial fractures (RUST) assessed healing on radiographs. Ninety-nine participants had follow-up at three months and eighty-one at twelve months.
The prespecified contrasts for the clinical and radiographic outcomes were null. Raising serum vitamin D therefore did not establish improved healing on those comparisons. A post hoc high-dose clinical signal was reported using 80% confidence intervals and p values around 0.16 and 0.18. Those exploratory criteria were intended to screen for a possible signal, not to provide conventional confirmatory evidence of efficacy.
This distinction is not a technicality. A finding selected after examining results carries a different level of assurance from a prespecified primary comparison. Small groups, incomplete adherence, attrition, imputation and multiple comparisons also affect interpretation. The trial does not prove equivalence between every regimen, but it cannot be reported as having demonstrated a clear high-dose healing benefit.
The link between a blood measurement and a functional outcome is explored in Vitamin D Status vs Vitamin D Effect. In fracture research, the meaningful question is not simply whether the intervention raises the concentration. It is whether patients heal better on outcomes that matter, with an acceptable balance of effects.
Bolus dosing and estimated bone mechanics
Heyer and colleagues studied postmenopausal women with distal-radius fractures treated without surgery. Thirty-two women were randomised, and thirty completed the study. Two bolus-dose regimens, using 30,000 or 75,000 IU at the first and third visits, six weeks apart, were compared with no supplementation over twelve weeks. These were intermittent bolus exposures, not daily doses.
The higher-dose arm had adverse changes in selected trabecular and estimated compression outcomes, accompanied by a CTX signal. Several other density or mechanical estimates were null, and patient-rated wrist outcomes did not improve. The lower-dose comparison was also null. The result is therefore mixed and endpoint-specific, not uniform deterioration of bone formation or function.
The mechanical measurements were derived from high-resolution imaging and modelling. They were not direct measurements of the force needed to break a healing bone. Their validity in the fracture setting, baseline differences in severity and osteoporosis, replacement participants, lack of placebo and multiple comparisons all constrain the conclusion. Non-fasting CTX measurements add another source of variability.
The study is relevant to Vitamin D and Bone because it challenges the assumption that more supplementation must strengthen every healing fracture. It does not establish general harm from ordinary daily vitamin D. Its population, fracture site and delivery pattern differ substantially from those of Vita-Shock.
A positive regimen comparison with lower confidence
Selvaraj and colleagues studied fifty adults with mixed long-bone fractures and low vitamin D concentrations. Twenty-five participants received 1,000 IU daily and twenty-five received 60,000 IU weekly for twelve weeks; both groups also received calcium. The reported mean union time was 18.6 weeks in the daily group and 15.9 weeks in the weekly group, with p=0.002.
At twenty-four weeks, union was reported in 84% and 96%, respectively, but this comparison was not statistically significant. One episode of hypercalcaemia occurred in the weekly group. Alkaline-phosphatase differences were null. Reporting only the mean union-time result would therefore give an incomplete account of efficacy and safety observations.
The comparison confounded dosing frequency with an approximately 8.6-fold difference in total weekly dose. It did not include a vitamin-D-free control. The study therefore cannot isolate whether frequency, total exposure, another difference between groups or chance explains the finding. Concealment and blinding were unclear, registry and recruitment details were missing, and the ascertainment of precise union times between scheduled visits was insufficiently explained.
Mixed bones and fixation methods, lack of validated functional outcomes and limited adherence information further reduce confidence. This paper is retained because an accurate synthesis must include the positive report, rather than describing all human fracture evidence as null. Its limitations prevent it from establishing an optimal regimen or a general treatment recommendation.
Metabolite-specific repair in animal models
Martineau’s 2018 work investigated a distinct vitamin D metabolite, 24R,25-dihydroxyvitamin D3. Cyp24a1-null survivor mice and chondrocyte-specific Fam57b deletion were used alongside rescue experiments. The findings supported a 24R,25-dihydroxyvitamin D3/FAM57B2/lactosylceramide route contributing to endochondral fracture repair.
The repair defect was transient, and calcitriol did not substitute for the relevant rescue. Lactosylceramide could act downstream in the knockout setting. This suggests that vitamin D-related repair cannot always be explained solely by increasing calcitriol. The broader metabolic distinction is introduced in Vitamin D Enzyme Pathways (CYP27B1 / CYP24A1).
A 2020 follow-up treated wild-type female mice after tibial osteotomy, starting on day three. Selected callus stiffness and modulus outcomes improved with 24R,25-dihydroxyvitamin D3 or lactosylceramide, particularly around day eighteen. Not every structural or mechanical measurement improved. The two papers came from the same programme, so they are complementary experiments rather than independent laboratory validation.
Small groups, systemic metabolite changes in knockout survivors, supraphysiological rescue and limited safety observation restrict translation. The follow-up also lacked reported randomisation and blinding and disclosed patent-inventor interests. These experiments strengthen a preclinical mechanism but do not establish that either compound improves human fracture healing or is safe for long-term clinical use.
Inflammation resolution and structural recovery
Repair requires a coordinated immune response. Early inflammation can help organise the response to injury, while persistent or excessive inflammation can interfere with later recovery. A treatment that changes inflammatory markers may therefore help or hinder depending on when, where and how it acts. The relevant physiological context is Vitamin D and Inflammatory Signalling, but the studies must demonstrate the repair consequence rather than assume it.
Ultraviolet injury and myeloid autophagy
Das and colleagues examined ultraviolet B injury in female mice, using injected 25-hydroxyvitamin D after injury. Cultured macrophage experiments used calcitriol. Reduced skin injury accompanied autophagy-associated changes and an M2-associated marker pattern. Myeloid Atg7 deletion weakened the protective response, supplying evidence that the recycling pathway contributed to the outcome.
The result does not establish a uniquely macrophage-specific mechanism because the targeting affects a broader myeloid population. M1 and M2 are simplified descriptions of selected immune-cell markers, not complete categories of cell behaviour. The pharmacological inhibitor used was also not specific to one autophagy action. Reduced TUNEL-positive damage added an injury-related endpoint but did not map a complete apoptotic pathway.
Human biopsies reused material from an earlier trial and did not show a significant LC3/CD163 signal. They cannot be counted as an independent clinical confirmation. The study’s relevance is a partly tested connection between cellular recycling, immune response and skin injury recovery. It does not supply a human sunburn treatment or justify translating an injected metabolite into an oral vitamin D3 dose.
An anti-inflammatory shift can be mistimed
Wasnik and colleagues provide an important contrasting case. In vitamin-D-sufficient male mice with fractures, early local calcitriol reduced M1-associated macrophage signals and promoted M2-associated differentiation. Nevertheless, callus and union outcomes were impaired. A cellular profile often described as favourable did not ensure better structural repair.
When treatment began on day ten, the overall healing outcomes did not show significant acceleration or impairment, although trabecular number increased. The study therefore supports a timing-dependent interpretation rather than the assertion that every late endpoint was unchanged. It suggests that suppressing part of the early inflammatory response can interfere with processes needed for later recovery.
The mechanism was not fully isolated. Small groups, absent reporting of randomisation and blinding, and lack of macrophage-specific receptor deletion or rescue leave alternative explanations open. Direct actions on mesenchymal cells were not excluded. The finding concerns local active hormone in a particular mouse model, not a demonstration that oral vitamin D3 harms healing in deficient patients.
Das and Wasnik should not be treated as exact replications with opposite answers. They differ in injury, compound, route and cellular setting. Their combined value is to show why inflammatory markers must be linked to actual tissue outcomes. Less inflammation is not a sufficient definition of successful repair.
Restoring structure is more than changing a marker
Tissue recovery also involves production and organisation of structural proteins, discussed in Vitamin D and Protein Metabolism. The selected studies did not establish that changing every protein marker improves strength or function. A scar score, radiographic union, modelled stiffness and a cell-culture marker each describe a different level of recovery.
The distinction from Vitamin D and Regeneration is also useful. Closing a wound or stabilising a fracture does not necessarily recreate the original tissue in every respect. Similarly, none of these trials demonstrated reversal of the persistent cell states described in Vitamin D and Cellular Senescence. Those topics are related physiological questions, not additional outcomes supplied by the repair evidence.
Across the human studies, small samples and heterogeneous settings make broad generalisation difficult. The burn signal is encouraging within its trial but requires confirmation. Prespecified fracture outcomes were null in one study; selected estimated mechanics worsened in another; a weaker regimen comparison reported faster mean union. These results should remain visible together, with their different confidence levels and populations.
Conclusion
Vitamin D-related interventions can influence repair biology, but clinical outcomes are mixed and mechanisms depend on context. A small burn trial reported better wound scores, while fracture studies did not establish a consistent benefit. Animal work shows both metabolite-specific support for repair and impairment when early inflammation is altered. The evidence supports careful reporting of defined outcomes, not a universal promise of faster healing or a dosing recommendation.
Original research
Das LM et al. 2019. Vitamin D improves sunburns by increasing autophagy in M2 macrophages. Autophagy. 15(5): 813. DOI: 10.1080/15548627.2019.1569298. PMID: 30661440.
Ghadimi E et al. 2025. Effects of vitamin D3 supplementation on the recovery of hospitalized burn patients: a randomized double-blind controlled trial. BMC nutrition. 11(1): 37. DOI: 10.1186/s40795-025-01024-2. PMID: 39930539.
Wasnik S et al. 2018. 1,25-Dihydroxyvitamin D suppresses M1 macrophages and promotes M2 differentiation at bone injury sites. JCI insight. 3(17): e98773. DOI: 10.1172/jci.insight.98773. PMID: 30185660.
Slobogean GP et al. 2023. Effect of Vitamin D3 Supplementation on Acute Fracture Healing: A Phase II Screening Randomized Double-Blind Controlled Trial. JBMR plus. 7(1): e10705. DOI: 10.1002/jbm4.10705. PMID: 36699638.
Heyer FL et al. 2021. The Effect of Bolus Vitamin D3 Supplementation on Distal Radius Fracture Healing: A Randomized Controlled Trial Using HR-pQCT. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research. 36(8): 1492. DOI: 10.1002/jbmr.4311. PMID: 33877707.
Selvaraj NV et al. 2026. Effect of Vitamin D Supplementation Regimens on Fracture Healing and Serum Biomarker Profile in Long-Bone Fractures: A Prospective Randomized Study. Journal of orthopaedic case reports. 16(5): 401-409. DOI: 10.13107/jocr.2026.v16.i05.7314. PMID: 42130995.
Martineau C et al. 2018. Optimal bone fracture repair requires 24R,25-dihydroxyvitamin D3 and its effector molecule FAM57B2. The Journal of clinical investigation. 128(8). DOI: 10.1172/jci98093. PMID: 30010626.
Martineau C et al. 2020. Preclinical safety and efficacy of 24R,25-dihydroxyvitamin D3 or lactosylceramide treatment to enhance fracture repair. Journal of orthopaedic translation. 23: 77-88. DOI: 10.1016/j.jot.2020.03.013. PMID: 32518749.
Related reading
A comparative study of the injury patterns and inflammatory response between suicidal and unintentional falls from height in Germany
This study aims to analyse injury patterns, inflammatory responses and complication rates in people who have jumped to their death, compared to those who have fallen unintentionally.
Original paper ↗Read more →Effect of Vitamin D3 Supplementation on Acute Fracture Healing: A Phase II Screening Randomized Double‐Blind Controlled Trial
One hundred two patients with a mean age of 29 years (standard deviation 8) were randomized.
Original paper ↗Read more →Inflammation: and Gut-Homing Macrophages, Engineered to De Novo Overexpress Active Vitamin D, Promoted the Regenerative Function of Intestinal Stem Cells
Available drugs aim to suppress gut inflammation.
Original paper ↗Read more →Vitamin D, Injury Recovery and Inflammation Resolution: Study Summary
A summary of vitamin D burn and fracture studies, with mixed repair outcomes and evidence on the timing of inflammatory responses.
Read more →Efficacy of Danshen injection combined with Calcitriol and Calcium/Vitamin-D for the treatment of osteoporotic fractures: A retrospective case-control study
To explore the efficacy of Danshen injection combined with calcitriol and calcium/Vitamin-D in the treatment of osteoporotic fractures.
Original paper ↗Read more →Effects of macro: and micronutrient intake on bone mineral density, osteoporotic fracture risk, inflammation, and functional rehabilitation outcomes in orthopedic patients: a systematic review and meta-analysis
The systematic review examined 95 studies which were organized into seven distinct outcome domains.
Original paper ↗Read more →Exploring the Association Between Platelet Count, the Systemic Immune Inflammation Index, and Fracture Risk in Postmenopausal Women with Osteoporosis: A Cross-Sectional Study
This study aimed to investigate the association between platelet indices and the derived systemic immune inflammation index (SII) with fracture risk in postmenopausal women.
Original paper ↗Read more →Sex hormone-binding globulin increases lumbar fracture risk via bone density, inflammation, and insulin pathways
We investigated whether genetically higher SHBG increases lumbar fracture (LF) risk and identified the biological pathways mediating this effect, including bone mineral density (BMD), C-reactive protein (CRP), and insulin use.
Original paper ↗Read more →Modulation of renal inflammation and tubular injury by calcitriol in patients with early diabetic kidney disease: a randomized controlled trial
This double-blind, randomized controlled trial investigated the effects of calcitriol supplementation on kidney injury biomarkers in patients with early DKD.
Original paper ↗Read more →Comparative study on the efficacy of menadione, zoledronic acid, and calcitriol in combination with PKP for the treatment of osteoporotic vertebral compression fractures in extremely elderly patients
Patients with osteoporotic vertebral compression fractures (OVCF) were assigned into 4 groups.
Original paper ↗Read more →Effect of sarcopenia combined with Metabolic Syndrome (MS) on the prognosis of intertrochanteric fractures: a retrospective clinical study
Preoperative, perioperative and postoperative data of the MS, sarcopenia, and combined groups were compared with the control group.
Original paper ↗Read more →Falls, fracture and frailty risk in multiple sclerosis: a Mendelian Randomization study to identify shared genetics
Our objective is to identify shared pleiotropic genetic effects and estimate the causal relationship between MS and musculoskeletal disorders.
Original paper ↗Read more →Improving osteoporosis treatment rates in inpatients admitted with hip fracture: A healthcare improvement initiative in a tertiary referral hospital
Its aim was to standardize assessment and treatment of osteoporosis in patients admitted with hip fracture.
Original paper ↗Read more →Meat consumption and the risk of hip fracture in women and men: two prospective Swedish cohort studies
Associations were investigated using multivariable Cox and linear regression analyses.
Original paper ↗Read more →MiR-642a-3p increases the risk of postmenopausal osteoporosis and fractures by targeting INO80
Postmenopausal osteoporosis (PMO), a metabolic bone disorder from estrogen deficiency, disrupts the balance between bone resorption and formation.
Original paper ↗Read more →Calcitriol Reduces the Inflammation, Endothelial Damage and Oxidative Stress in AKI Caused by Cisplatin
Cisplatin treatment is one of the most commonly used treatments for patients with cancer.
Original paper ↗Read more →Vertebral fractures in patients with inflammatory bowel disease COMPARED with a healthy population: a prospective case-control study
Information about anthropometric parameters, toxins, previous fractures, and parameters related to this disease were evaluated.
Original paper ↗Read more →Protective effect of calcitriol on rhabdomyolysis-induced acute kidney injury in rats
This study evaluated the effect of calcitriol administration in AKI induced by rhabdomyolysis and its relationship with oxidative damage and inflammatory process.
Original paper ↗Read more →Effect of Paricalcitol vs Calcitriol on Hemoglobin Levels in Chronic Kidney Disease Patients: A Randomized Trial
Therefore, we conducted a study to determine whether paricalcitol, compared to calcitriol, improves anemia in patients with chronic kidney disease (CKD).
Original paper ↗Read more →Perioperative risk factors in patients with a femoral neck fracture: influence of 25-hydroxyvitamin D and C-reactive protein on postoperative medical complications and 1-year mortality
This study examined the association of 25-hydroxyvitamin D (25(OH)D) and C-reactive protein (CRP) with postoperative medical complications and one year mortality of elderly patients sustaining a low-energy cervical hip fracture scheduled for surgery.
Original paper ↗Read more →Vitamin D and Inflammatory Signalling
Learn how vitamin D relates to inflammatory signalling, including initiation, regulation, resolution, cytokine communication, metabolic links, and tissue specific responses.
Read more →Original sources
Vitamin D improves sunburns by increasing autophagy in M2 macrophages
Published in Autophagy. 15(5): 813. DOI: 10.1080/15548627 (2019).
Publication details
Das LM et al. 2019. Vitamin D improves sunburns by increasing autophagy in M2 macrophages. Autophagy. 15(5): 813. DOI: 10.1080/15548627.2019.1569298. PMID: 30661440.
Effects of vitamin D3 supplementation on the recovery of hospitalized burn patients: a randomized double-blind controlled trial
Ghadimi E et al. 2025.
Publication details
Ghadimi E et al. 2025. Effects of vitamin D3 supplementation on the recovery of hospitalized burn patients: a randomized double-blind controlled trial. BMC nutrition. 11(1): 37. DOI: 10.1186/s40795-025-01024-2. PMID: 39930539.
1,25-Dihydroxyvitamin D suppresses M1 macrophages and promotes M2 differentiation at bone injury sites
Wasnik S et al. 2018.
Publication details
Wasnik S et al. 2018. 1,25-Dihydroxyvitamin D suppresses M1 macrophages and promotes M2 differentiation at bone injury sites. JCI insight. 3(17): e98773. DOI: 10.1172/jci.insight.98773. PMID: 30185660.
Effect of Vitamin D3 Supplementation on Acute Fracture Healing: A Phase II Screening Randomized Double‐Blind Controlled Trial
One hundred two patients with a mean age of 29 years (standard deviation 8) were randomized.
Publication details
Slobogean GP et al. 2023. Effect of Vitamin D3 Supplementation on Acute Fracture Healing: A Phase II Screening Randomized Double-Blind Controlled Trial. JBMR plus. 7(1): e10705. DOI: 10.1002/jbm4.10705. PMID: 36699638.
The Effect of Bolus Vitamin D3 Supplementation on Distal Radius Fracture Healing: A Randomized Controlled Trial Using HR-pQCT
Heyer FL et al. 2021.
Publication details
Heyer FL et al. 2021. The Effect of Bolus Vitamin D3 Supplementation on Distal Radius Fracture Healing: A Randomized Controlled Trial Using HR-pQCT. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research. 36(8): 1492. DOI: 10.1002/jbmr.4311. PMID: 33877707.
Effect of Vitamin D Supplementation Regimens on Fracture Healing and Serum Biomarker Profile in Long-Bone Fractures: A Prospective Randomized Study
Published in Journal of orthopaedic case reports. 16(5): 401-409. DOI: 10.13107/jocr (2026).
Publication details
Selvaraj NV et al. 2026. Effect of Vitamin D Supplementation Regimens on Fracture Healing and Serum Biomarker Profile in Long-Bone Fractures: A Prospective Randomized Study. Journal of orthopaedic case reports. 16(5): 401-409. DOI: 10.13107/jocr.2026.v16.i05.7314. PMID: 42130995.
Optimal bone fracture repair requires 24R,25-dihydroxyvitamin D3 and its effector molecule FAM57B2
Martineau C et al. 2018.
Publication details
Martineau C et al. 2018. Optimal bone fracture repair requires 24R,25-dihydroxyvitamin D3 and its effector molecule FAM57B2. The Journal of clinical investigation. 128(8). DOI: 10.1172/jci98093. PMID: 30010626.
Preclinical safety and efficacy of 24R,25-dihydroxyvitamin D3 or lactosylceramide treatment to enhance fracture repair
Published in Journal of orthopaedic translation. 23: 77-88. DOI: 10.1016/j.jot (2020).
Publication details
Martineau C et al. 2020. Preclinical safety and efficacy of 24R,25-dihydroxyvitamin D3 or lactosylceramide treatment to enhance fracture repair. Journal of orthopaedic translation. 23: 77-88. DOI: 10.1016/j.jot.2020.03.013. PMID: 32518749.